X
<

What Drove Eli Lilly in 3Q17?

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 10
What Drove Eli Lilly in 3Q17? PART 10 OF 12

How Eli Lilly’s Animal Health Products Performed in 3Q17

Animal health revenue trends

In 3Q17, Eli Lilly’s (LLY) Animal Health segment reported revenues of $740.6 million, a ~5% increase on a year-over-year (or YoY) basis and a 6% decline on a quarter-over-quarter basis. In 3Q17, in the US and international markets, Eli Lilly’s Animal Health segment reported revenues of $353.0 million and $387.6 million, respectively, compared to $338.6 million and $367.6 million in 3Q16.

Eli Lilly’s Animal Health segment reported revenues of $2.3 billion in the first nine months of 2017. In the US and international markets, animal health products generated revenues of $1.2 billion and $1.1 billion, respectively, in the first nine months of 2017.

How Eli Lilly’s Animal Health Products Performed in 3Q17

Interested in ZTS? Don't miss the next report.

Receive e-mail alerts for new research on ZTS

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

In 3Q17, among animal health products, Eli Lilly’s companion animal health products generated revenues of $252.2 million compared to $186.9 million in 3Q16. Eli Lilly’s companion animal health products reported YTD September 2017 revenues of $825.3 million. In the US and international markets, companion animal health products reported YTD September 2017 revenues of $568 million and $257 million, respectively.

Eli Lilly’s other pharmaceuticals

Eli Lilly’s other pharmaceuticals include cardiology products (Zalutia and Livalo), neurology products (Amyvid and Symbyax), endocrinology products (Actos and HumaPen), and Pharma products (Ceclor, Keflex, Vancocin, and others).

In 3Q17, Vancocin reported revenues of $23.7 million compared to $23.5 million in 3Q16. Vancocin reported revenues of $75.8 million in the first nine months of 2017. In 3Q17, Eli Lilly’s oncology drug Portrazza reported revenues of $2.3 million and YTD September 2017 revenues of $8.2 million. Portrazza is used for the treatment of individuals with non-squamous non-small cell lung cancer.

Eli Lilly’s peers in the animal health market include Zoetis (ZTS), Merck (MRK), Merial (a division of Sanofi), Bayer (BAYZF), and Boehringer Ingelheim. In 3Q17, Merck’s animal health and Zoetis reported revenues of $1.0 billion and $1.3 billion, respectively. The iShares Select Dividend ETF (DVY) invests ~0.90% of its total portfolio holdings in Eli Lilly.

X

Please select a profession that best describes you: